What is Enformia?
Enformia operates at the intersection of cognitive psychology and digital health, providing the Cogsuite platform to address the growing demand for precise, remote cognitive impairment detection. By leveraging contemporary neuroscience, the company offers a sophisticated suite of tools that facilitate reliable data management for researchers and clinicians alike. Beyond its core assessment capabilities, Enformia maintains a comprehensive library of over 500 self-report instruments, serving a diverse user base that ranges from general populations to patients managing chronic health conditions. Supported by the National Cancer Institute, the platform is positioned as a critical resource for longitudinal studies and clinical diagnostics, effectively digitizing complex neuropsychological evaluations for modern healthcare environments.
How much funding has Enformia raised?
Enformia has raised a total of $48K across 1 funding round:
Debt
$48K
Debt (2021): $48K with participation from PPP
Key Investors in Enformia
PPP
Public-Private Partnership
What's next for Enformia?
With this latest infusion of capital, Enformia is well-positioned to accelerate its product development roadmap and expand its footprint within the clinical research sector. The strategic focus will likely shift toward enhancing the scalability of the Cogsuite platform, potentially integrating more advanced machine learning algorithms to refine diagnostic accuracy. As the company moves deeper into its Series B/C lifecycle, the emphasis will remain on strengthening partnerships with healthcare institutions and research organizations. By prioritizing the integration of its self-report systems with broader electronic health record ecosystems, Enformia aims to solidify its role as a foundational player in the digital cognitive health market, ensuring that its assessment tools remain at the forefront of clinical innovation.
See full Enformia company page
